SecBot SecBot

SLGL

Sol-Gel Technologies Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001684693 Biotech & Drug Discovery
$69.63 +0.18 (+0.26%)
Oct 26 4:00 PM ET · prev $69.45
Market cap
$220.6M
Micro cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
$152.50
+119% · range $110.00–195.00
Next earnings
Nov 18
in 23 days · EPS est. −$2.07
1 year
+74.9%
from $39.81 · Oct 27
30 days
+0.3%
from $69.45
52-week range
$30.64–97.97
−29% from high · low Nov 7
Avg volume 20D
39.7K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$7.4M
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read BULLISH 10 reports · 90 days
Balance 0 bearish · 4 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 8/10 ·Next Earnings date, Nov 18, 2026
Strongest BULLISH Opaleye Management Inc., a 10% owner of Sol-Gel Technologies, executed a concentrated open-market buying…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $7.4M at an average $70.16. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$2.580 → −$2.073 over 90 days.

  • TrendRANGE

    0% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
Phoenix Financial Ltd.TRIM146,147$10.8M
HRT FINANCIAL LPADD6,256$463.0K
UBS Group AGTRIM416$30.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy2Buy6Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +119%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 19, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Oct 14, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
Jul 20, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 24, 2026Mizuho
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$7.4M
bought · 1 insider
$0
sold · 0 insiders
−0.8%
vs their $70.16 cost
DateInsiderTypeValue
Sep 11, 2026
Opaleye Management Inc.
10%+ Owner
BUY$98.5K
Sep 10, 2026
Opaleye Management Inc.
10%+ Owner
BUY$108.9K
Sep 9, 2026
Opaleye Management Inc.
10%+ Owner
BUY$212.8K
Sep 8, 2026
Opaleye Management Inc.
10%+ Owner
BUY$233.0K
Sep 8, 2026
Opaleye Management Inc.
10%+ Owner
BUY$32.7K
Sep 4, 2026
Opaleye Management Inc.
10%+ Owner
BUY$144.9K
Sep 4, 2026
Opaleye Management Inc.
10%+ Owner
BUY$63.8K
Sep 2, 2026
Opaleye Management Inc.
10%+ Owner
BUY$62.1K

Earnings setup

Estimates
Nov 18
reports in 23 days
−$2.07
EPS estimate, this quarter
+20%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$2.07-$3.01–-$1.54+31.1%$150.0K
Next Q-$2.04-$2.67–-$1.68+23.6%$175.0K
Current FY-$7.75-$11.78–-$5.68+34.2%$1.0M
Next FY-$8.03-$15.20–-$4.92+4.1%$566.7K

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 18, 2026 Clinical trial readout
Results Pending: Patidegib Topical Gel (Phase 3) — Completed 59d ago
Trial: Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of A
Oct 6, 2026 SEC
Sol-Gel Technologies filed its proxy statement for the Annual Meeting of Shareholders scheduled for November 17, 2026…
6-K — Impact 3/10
Sep 30, 2026 SEC
Sol-Gel Technologies announced it will host a KOL Investor Day on October 14, 2026, focused on its lead candidate…
6-K — Impact 3/10
Sep 17, 2026 SEC
Sol-Gel Technologies announced last patient last visit (LPLV) in its pivotal Phase 3 trial of SGT-610 (patidegib gel…
6-K — Impact 5/10
Sep 11, 2026 Insider
Opaleye Management Inc. bought 1,493 shares
10%+ Owner @ $65.95 ($98.5K)
Sep 10, 2026 Insider
Opaleye Management Inc. bought 1,631 shares
10%+ Owner @ $66.80 ($108.9K)
Sep 9, 2026 Insider
Opaleye Management Inc. bought 3,097 shares
10%+ Owner @ $68.71 ($212.8K)
Jun 30, 2026 Inst.
Phoenix Financial Ltd. — TRIM
146,147 shares ($10.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
SLGL Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Oct 18, 2026
Trial readout
Results Pending: Patidegib Topical Gel (Phase 3) — Completed 59d ago
Trial: Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Sponsor: Sol-Gel…
Sep 30, 2026
Press release
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
NESS ZIONA, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for…
Sep 18, 2026
Trial readout
Results Pending: Patidegib Topical Gel (Phase 3) — Completed 29d ago
Trial: Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Sponsor: Sol-Gel…
Aug 20, 2026
Earnings
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
NESS ZIONA, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for…
Aug 13, 2026
Earnings date
SLGL Q2 2026 Earnings Scheduled — 2026-08-13

SecBot reports

15 filings · 1 press release · 5 bullish · 0 bearish · 2 mixed · 8 neutral
All SLGL filing & press-release reports (16)